BE2013C060I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C060I2
BE2013C060I2 BE2013C060C BE2013C060C BE2013C060I2 BE 2013C060 I2 BE2013C060 I2 BE 2013C060I2 BE 2013C060 C BE2013C060 C BE 2013C060C BE 2013C060 C BE2013C060 C BE 2013C060C BE 2013C060 I2 BE2013C060 I2 BE 2013C060I2
Authority
BE
Belgium
Application number
BE2013C060C
Other languages
Dutch (nl)
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24535786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C060(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of BE2013C060I2 publication Critical patent/BE2013C060I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2013C060C 2000-08-03 2013-10-30 BE2013C060I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/632,508 US6387383B1 (en) 2000-08-03 2000-08-03 Topical low-viscosity gel composition
PCT/US2001/023341 WO2002011683A1 (en) 2000-08-03 2001-07-24 Topical gel delivery system

Publications (1)

Publication Number Publication Date
BE2013C060I2 true BE2013C060I2 (en) 2020-12-15

Family

ID=24535786

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C060C BE2013C060I2 (en) 2000-08-03 2013-10-30

Country Status (25)

Country Link
US (2) US6387383B1 (en)
EP (2) EP2052714B1 (en)
JP (1) JP4988129B2 (en)
KR (2) KR100840169B1 (en)
CN (2) CN1460013B (en)
AR (1) AR030093A1 (en)
AT (1) ATE429922T1 (en)
AU (2) AU7900201A (en)
BE (1) BE2013C060I2 (en)
BR (1) BR0113247A (en)
CA (1) CA2417646C (en)
CY (3) CY1109189T1 (en)
DE (1) DE60138549D1 (en)
DK (2) DK1304992T3 (en)
ES (2) ES2437321T3 (en)
FR (1) FR14C0053I1 (en)
HK (1) HK1125847A1 (en)
LU (1) LU92401I2 (en)
MX (1) MXPA03001006A (en)
PL (1) PL213237B1 (en)
PT (2) PT2052714E (en)
RU (1) RU2251410C2 (en)
SI (2) SI2052714T1 (en)
WO (1) WO2002011683A1 (en)
ZA (1) ZA200301037B (en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU770803B2 (en) 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
ATE216875T1 (en) 1999-01-27 2002-05-15 Idea Ag NON-INVASIVE VACCINATION THROUGH THE SKIN
PT1031347E (en) 1999-01-27 2002-09-30 Idea Ag TRANSNATIONAL TRANSMISSION / IMMUNIZATION WITH MOST ADAPTABLE VEHICLES
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
WO2002089743A2 (en) 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
EA009024B1 (en) * 2002-06-25 2007-10-26 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Pharmaceutical composition for transdermal delivery of an active agent (variants)
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US6906014B2 (en) * 2002-09-10 2005-06-14 Permatex, Inc. Stabilized topical composition
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
ES2637956T3 (en) 2003-01-24 2017-10-18 Stiefel Research Australia Pty Ltd Pharmaceutical foam
US20060135607A1 (en) * 2003-02-07 2006-06-22 Mochida Pharmaceutical Co., Ltd. Drug for improving prognosis for subarachnoid hemorrhage
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
JP2007502288A (en) 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
WO2005027939A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
KR101106812B1 (en) 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
MY144021A (en) 2003-09-19 2011-07-29 Drugtech Corp Pharmaceutical delivery system
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
WO2005028528A1 (en) * 2003-09-23 2005-03-31 Akciju Sabiedriba 'olainfarm' 3,5-dimethyl-1-adamantyl-ammonium polymeric salts and the use thereof in the form of antiviral agents
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546273A (en) 2003-10-03 2009-05-31 Coley Pharm Group Inc Alkoxy substituted imidazoquinolines
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
JP2007511535A (en) * 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー Hydroxylamine substituted imidazo ring compounds
RU2409576C2 (en) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Systems containing imidazole ring with substitutes, and methods of obtaining said systems
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
KR101249639B1 (en) * 2003-12-30 2013-04-01 오클루스 이노바티브 사이언시즈 인코포레이티드 Oxidative reductive potential water solution, processes for producing same and methods of using the same
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US7662855B2 (en) * 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US20050255131A1 (en) * 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
US20060014834A1 (en) * 2004-05-11 2006-01-19 Mohan Vishnupad Retinoid solutions and formulations made therefrom
ES2647618T3 (en) 2004-05-25 2017-12-22 Galderma Pharma S.A. Compounds, formulations and procedures to treat or prevent inflammatory skin disorders
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
FR2887149B1 (en) * 2005-06-17 2007-08-03 Galderma Sa PROCESS FOR SOLUBILIZING THE METRONIDAZOLE
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
ITMI20041376A1 (en) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma METHOD OF PREPARATION OF A BIOCOMPATIBLE POLYMERIC SYSTEM FOR PHARMACOLOGICAL RELEASE IN TOPICAL USE AND USE OF THE SYSTEM
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
MX2007005449A (en) * 2004-11-09 2007-12-07 Imaginative Res Associates Inc Retinoid solutions and formulations made therefrom.
KR20070086045A (en) * 2004-11-12 2007-08-27 이데아 아게 Extended surface aggregates in the treatment of skin conditions
ES2392648T3 (en) 2004-12-30 2012-12-12 3M Innovative Properties Company Substituted chiral compounds containing a condensed 1,2-imidazo-4,5-c core
JP5543068B2 (en) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー Chiral fused [1,2] imidazo [4,5-c] cyclic compound
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006107851A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008535832A (en) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド Pyrazolopyridine-1,4-diamine and analogs thereof
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
MX2007013631A (en) * 2005-05-09 2008-01-24 Drugtech Corp Modified-release pharmaceutical compositions.
ES2607454T3 (en) * 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Method and composition for transdermal testosterone delivery
AR054805A1 (en) * 2005-06-29 2007-07-18 Stiefel Laboratories TOPICAL COMPOSITIONS FOR SKIN TREATMENT
US20090117190A1 (en) * 2005-08-23 2009-05-07 Nissan Chemical Industries, Ltd. Sustained-release preparation
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2635986A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
KR20080083190A (en) * 2006-01-05 2008-09-16 드러그테크 코포레이션 Drug delivery system for bioadhesion to a vulvovaginal surface
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
PL2010133T3 (en) 2006-03-31 2017-08-31 Stiefel Research Australia Pty Ltd Foamable suspension gel
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008049020A2 (en) 2006-10-17 2008-04-24 Nuvo Research Diclofenac gel
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
US20080312245A1 (en) * 2007-06-12 2008-12-18 Longyan Xiao Methods and compositions for treating acne and other infectious diseases
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
JP2011500687A (en) * 2007-10-18 2011-01-06 メディシス・ファーマシューティカル・コーポレーション Aqueous retinoid and benzoyl peroxide gels
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2704946C (en) 2007-11-13 2013-09-24 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
NZ586302A (en) 2007-12-21 2013-03-28 Galderma Lab Inc Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
US20090176719A1 (en) * 2008-01-07 2009-07-09 Liolabs Llc Compositions and methods for treating perioral dermatitis
RU2497515C2 (en) * 2008-03-17 2013-11-10 Гленмарк Фармасьютикалс Лимитед Topical formulation containing adapalene microspheres and clindamycin
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2724804A1 (en) * 2008-05-16 2009-11-19 Galderma Research & Development Therapy regimen for treating acne related diseases
EP2299810B1 (en) 2008-06-05 2020-01-01 Bausch Health Ireland Limited Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
CA2728727C (en) * 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
ES2637447T3 (en) 2009-08-31 2017-10-13 Dr. Reddy's Laboratories Ltd. Topical formulations containing a steroid
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN106038476B (en) 2010-03-26 2020-04-17 盖尔德马研究及发展公司 Improved methods and compositions for safe and effective treatment of erythema
JP5747392B2 (en) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント Improved methods and compositions for safe and effective treatment of telangiectasia
CN103209690A (en) 2010-06-30 2013-07-17 盖尔德马研究及发展公司 Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
CA2811061A1 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
AR083651A1 (en) 2010-10-21 2013-03-13 Galderma Sa BRIMONIDINE COMPOSITIONS IN GEL AND METHODS OF USE
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013019974A1 (en) 2011-08-02 2013-02-07 Medicis Pharmaceutical Corporation Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea
RU2014119919A (en) 2011-10-19 2015-11-27 Галдерма С.А. METHOD FOR TREATING CAPILLARY HEMANGIOMES
JP2014530846A (en) 2011-10-19 2014-11-20 ガルデルマ ソシエテ アノニム Method for reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
UA109359C2 (en) 2011-11-10 2015-08-10 TREATMENT OF SKIN DISEASES AND STATES
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
RU2548714C2 (en) * 2012-05-03 2015-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical composition for treating acne and method for preparing it
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
RU2530644C2 (en) * 2012-11-01 2014-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Comedolytic pharmaceutical composition and method for preparing it
CN104995302B (en) 2013-01-16 2021-08-31 爱默蕾大学 CAS 9-nucleic acid complexes and uses related thereto
BR112016006426A2 (en) 2013-09-26 2017-08-01 Galderma Sa method of treating atrophic skin scars
US20150250697A1 (en) * 2014-03-07 2015-09-10 The Procter & Gamble Company Personal Care Compositions and Methods of Making Same
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
CN104473865A (en) * 2014-11-17 2015-04-01 重庆华邦制药有限公司 Desonide gel and preparation method thereof
EP3915542B1 (en) 2014-12-23 2023-11-22 Dyve Biosciences, Inc. Formulations for transdermal administration
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
PT3310389T (en) 2015-06-18 2020-11-11 Valeant Pharmaceuticals North America Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis
RU2699027C2 (en) 2015-07-13 2019-09-03 Др. Редди'С Лабораториз Лтд. Retinoid compositions for topical application
CN106474047A (en) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 A kind of desonide preparation stable to light
CN106474059A (en) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 A kind of more stable desonide lotion of quality
CN106474048A (en) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 A kind of more stable desonide gel preparation of quality
AU2017241767B2 (en) 2016-03-28 2021-07-22 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
WO2018213310A1 (en) 2017-05-15 2018-11-22 Cornell University Device and system for repairing intervertebral disc herniation and methods of use
US10779525B2 (en) 2018-01-16 2020-09-22 Zin Research LLC Treatment compound and method of application for hoof or foot disease in animals
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
WO2020097211A1 (en) * 2018-11-06 2020-05-14 Cote Tim Topical compositions comprising pentoxifylline and methods of treatment using the same
FR3090385B1 (en) * 2018-12-21 2021-01-08 Pf Medicament Emollient composition in the form of an emulsion
CN111743853A (en) * 2019-03-29 2020-10-09 天津金耀集团有限公司 External pharmaceutical composition of near-neutral hydrocortisone butyrate
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
US20220202841A1 (en) * 2020-12-24 2022-06-30 Erine A. Kupetsky Dermatological formulations for treatment of dermatitis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969516A (en) 1974-12-19 1976-07-13 Nelson Research & Development Company Composition and method for treatment of acne
US4497794A (en) 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4361584A (en) 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4247547A (en) 1979-03-19 1981-01-27 Johnson & Johnson Tretinoin in a gel vehicle for acne treatment
US4387107A (en) 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4692329A (en) 1980-12-08 1987-09-08 William H. Rorer, Inc. Erythromycin/benzoyl peroxide antiacne compositions
LU83173A1 (en) 1981-02-27 1981-06-05 Oreal NOVEL COSMETIC COMPOSITIONS FOR THE TREATMENT OF HAIR AND SKIN CONTAINING POWDER RESULTING FROM THE SPRAYING OF AT LEAST ONE PLANT AND A COHESION AGENT
US4514385A (en) 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
CH643138A5 (en) * 1983-08-29 1984-05-30 Mepha Ag INDOMETHACIN CONTAINING, gelatinous OINTMENT.
LU85111A1 (en) 1983-12-01 1985-09-12 Oreal ANTI-ACNETIC COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE SOLAR FILTER
US5446028A (en) 1985-12-12 1995-08-29 Dermik Laboratories, Inc. Anti-acne method and composition
FR2604357B1 (en) 1986-09-30 1988-12-02 Oreal PHARMACEUTICAL AND ANTI-ACNE COSMETIC COMPOSITION
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
JPH0825878B2 (en) * 1987-03-20 1996-03-13 ガルデルマ エスアー Topical metronidazole formulation
MY105521A (en) * 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
DE69029804T2 (en) 1989-06-07 1997-09-04 Gail S Bazzano VEHICLE WITH SLOW RELEASE TO REDUCE SKIN IRRITATION OF TOPICAL AGENTS CONTAINING RETINOIDS
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
GB9021320D0 (en) 1990-10-01 1990-11-14 Diomed Dev Ltd Compositions for topical application
US5380528A (en) 1990-11-30 1995-01-10 Richardson-Vicks Inc. Silicone containing skin care compositions having improved oil control
CZ90494A3 (en) * 1991-10-16 1994-07-13 Richardson Vicks Skin care preparation having the form of aqueous gel
JP3190441B2 (en) * 1992-07-20 2001-07-23 エーザイ株式会社 Stable formulation containing azelastine hydrochloride
US5549914A (en) * 1992-12-14 1996-08-27 Sween Corporation Heat stable wound care gel
RU2134101C1 (en) 1993-07-01 1999-08-10 Яманаухи Эуропе Б.В. Stable retinoid composition for local effect
US5482710A (en) 1993-07-30 1996-01-09 Chesebrough-Pond'usa Co., Division Of Conopco, Inc. Cosmetic composition for treatment of pimples and redness
US5382432A (en) 1993-11-15 1995-01-17 Elizabeth Arden Company, Division Of Conopco, Inc. Cosmetic method for treatment of skin
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
US5538732A (en) 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5445823A (en) 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
AT408067B (en) 1995-03-17 2001-08-27 Gebro Pharma Gmbh PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND METHOD FOR THE PRODUCTION THEREOF
EP0738510A3 (en) 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
US5750122A (en) 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
JP3193617B2 (en) * 1996-01-29 2001-07-30 カネボウ株式会社 Refreshing agent and composition for human body
US5891451A (en) 1996-06-25 1999-04-06 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters
FR2753626B1 (en) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma NOVEL TOPICAL COMPOSITIONS IN THE FORM OF A FLUID O / W EMULSION WITH A HIGH PRO-PENETRATING GLYCOL CONTENT
JPH1179948A (en) * 1997-09-12 1999-03-23 Noevir Co Ltd Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Also Published As

Publication number Publication date
AR030093A1 (en) 2003-08-13
ZA200301037B (en) 2004-02-09
CA2417646C (en) 2010-05-04
CY1109189T1 (en) 2014-07-02
CN101305982B (en) 2011-12-14
JP2004505900A (en) 2004-02-26
SI2052714T1 (en) 2013-11-29
CN1460013A (en) 2003-12-03
BR0113247A (en) 2003-06-24
US6517847B2 (en) 2003-02-11
LU92401I2 (en) 2014-05-19
EP2052714B1 (en) 2013-09-04
ES2326955T3 (en) 2009-10-22
CY1114646T1 (en) 2016-12-14
WO2002011683A1 (en) 2002-02-14
EP1304992A1 (en) 2003-05-02
ES2437321T3 (en) 2014-01-10
ATE429922T1 (en) 2009-05-15
EP2052714A1 (en) 2009-04-29
CN101305982A (en) 2008-11-19
AU7900201A (en) 2002-02-18
RU2251410C2 (en) 2005-05-10
EP1304992A4 (en) 2006-11-02
KR20030057526A (en) 2003-07-04
CY2014005I1 (en) 2014-07-02
HK1125847A1 (en) 2009-08-21
CN1460013B (en) 2011-12-14
CY2014005I2 (en) 2015-12-09
PL213237B1 (en) 2013-01-31
DE60138549D1 (en) 2009-06-10
KR100840169B1 (en) 2008-06-23
JP4988129B2 (en) 2012-08-01
EP1304992B1 (en) 2009-04-29
FR14C0053I1 (en) 2014-08-08
CA2417646A1 (en) 2002-02-14
PL360589A1 (en) 2004-09-06
US20020176891A1 (en) 2002-11-28
PT2052714E (en) 2013-10-17
PT1304992E (en) 2009-07-20
AU2001279002B2 (en) 2006-04-27
DK2052714T3 (en) 2013-10-14
DK1304992T3 (en) 2009-08-10
MXPA03001006A (en) 2005-02-25
US6387383B1 (en) 2002-05-14
KR20080036246A (en) 2008-04-25
SI1304992T1 (en) 2009-10-31

Similar Documents

Publication Publication Date Title
BE2016C059I2 (en)
BE2016C018I2 (en)
BE2015C062I2 (en)
BE2013C060I2 (en)
JP2003514215A5 (en)
JP2003500702A5 (en)
JP2003512131A5 (en)
AU2000236815A8 (en)
JP2002543539A5 (en)
JP2000228562A5 (en)
JP2000322366A5 (en)
JP2002158948A5 (en)
JP2003505948A5 (en)
JP2002543420A5 (en)
JP2001251115A5 (en)
CH694022C1 (en)
JP2003500132A5 (en)
JP2001205893A5 (en)
JP2002170055A5 (en)
BRPI0003419A (en)
JP2002001138A5 (en)
BY5768C1 (en)
CN3144584S (en)
CL2006000179A1 (en)
CN3139851S (en)